[go: up one dir, main page]

SMT202400145T1 - Intermedi per la preparazione di inibitori c-terminali di hsp90 - Google Patents

Intermedi per la preparazione di inibitori c-terminali di hsp90

Info

Publication number
SMT202400145T1
SMT202400145T1 SM20240145T SMT202400145T SMT202400145T1 SM T202400145 T1 SMT202400145 T1 SM T202400145T1 SM 20240145 T SM20240145 T SM 20240145T SM T202400145 T SMT202400145 T SM T202400145T SM T202400145 T1 SMT202400145 T1 SM T202400145T1
Authority
SM
San Marino
Prior art keywords
intermediates
preparation
hsp90 inhibitors
terminal hsp90
terminal
Prior art date
Application number
SM20240145T
Other languages
English (en)
Inventor
Bhaskar Reddy Kusuma
Teather Sundstrom
Brian S J Blagg
Original Assignee
Univ Kansas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Kansas filed Critical Univ Kansas
Publication of SMT202400145T1 publication Critical patent/SMT202400145T1/it

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/16Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings other than six-membered aromatic rings
    • C07C211/17Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings other than six-membered aromatic rings containing only non-condensed rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00Carboxylic acid amides
    • C07C233/01Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/18Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D319/00Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/041,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/081,3-Dioxanes; Hydrogenated 1,3-dioxanes condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20Carbocyclic rings
    • C07H15/203Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20Carbocyclic rings
    • C07H15/207Cyclohexane rings not substituted by nitrogen atoms, e.g. kasugamycins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
SM20240145T 2012-02-09 2013-02-08 Intermedi per la preparazione di inibitori c-terminali di hsp90 SMT202400145T1 (it)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261597004P 2012-02-09 2012-02-09
EP19193576.6A EP3656758B1 (en) 2012-02-09 2013-02-08 Intermediates for the preparation of c-terminal hsp90 inhibitors

Publications (1)

Publication Number Publication Date
SMT202400145T1 true SMT202400145T1 (it) 2024-05-14

Family

ID=47754998

Family Applications (2)

Application Number Title Priority Date Filing Date
SM20240145T SMT202400145T1 (it) 2012-02-09 2013-02-08 Intermedi per la preparazione di inibitori c-terminali di hsp90
SM20190660T SMT201900660T1 (it) 2012-02-09 2013-02-08 Inibitori c-terminali di hsp90

Family Applications After (1)

Application Number Title Priority Date Filing Date
SM20190660T SMT201900660T1 (it) 2012-02-09 2013-02-08 Inibitori c-terminali di hsp90

Country Status (25)

Country Link
US (7) US9422320B2 (it)
EP (3) EP2812341B1 (it)
JP (1) JP6121450B2 (it)
KR (1) KR102124109B1 (it)
CN (2) CN107474085B (it)
AU (1) AU2013216858C1 (it)
BR (1) BR112014019704B1 (it)
CA (1) CA2866814C (it)
CY (1) CY1122358T1 (it)
DK (2) DK2812341T3 (it)
EA (1) EA027147B1 (it)
ES (2) ES2974721T3 (it)
FI (1) FI3656758T3 (it)
HK (2) HK1205131A1 (it)
HR (2) HRP20240514T1 (it)
HU (2) HUE046939T2 (it)
LT (2) LT3656758T (it)
MX (1) MX361233B (it)
NZ (1) NZ629778A (it)
PL (2) PL2812341T3 (it)
PT (2) PT2812341T (it)
RS (2) RS65412B1 (it)
SI (2) SI2812341T1 (it)
SM (2) SMT202400145T1 (it)
WO (1) WO2013119985A1 (it)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202400145T1 (it) 2012-02-09 2024-05-14 Univ Kansas Intermedi per la preparazione di inibitori c-terminali di hsp90
EP3154964B1 (en) 2014-06-13 2023-04-05 The University of Kansas Triazole modified coumarin and biphenyl amide-based hsp90 inhibitors
CA2952029A1 (en) * 2014-06-24 2015-12-30 The University Of Kansas Biphenyl amides with modified ether groups as hsp90 inhibitors and hsp70 inducers
WO2016145219A1 (en) * 2015-03-10 2016-09-15 University Of Florida Research Foundation, Inc. Treatment of peripheral neuropathies
JP7402800B2 (ja) * 2017-12-20 2023-12-21 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング ヘテロ芳香族化合物
IL315865A (en) 2018-02-07 2024-11-01 Reata Pharmaceuticals Inc Co-crystal forms of a novobiocin analog and proline
EA202092727A1 (ru) * 2018-05-14 2021-04-20 Рита Фармасьютикалз, Инк. Биариламиды с модифицированными сахарными группами для лечения заболеваний, связанных с путем белка теплового шока
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2585091C (en) * 2004-11-03 2016-07-19 University Of Kansas Novobiocin analogues as anticancer agents
US9120774B2 (en) 2004-11-03 2015-09-01 University Of Kansas Novobiocin analogues having modified sugar moieties
US8212011B2 (en) 2004-11-03 2012-07-03 University Of Kansas Novobiocin analogues
US7622451B2 (en) 2004-11-03 2009-11-24 University Of Kansas Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders
US8212012B2 (en) 2004-11-03 2012-07-03 University Of Kansas Novobiocin analogues having modified sugar moieties
WO2007095586A2 (en) * 2006-02-14 2007-08-23 The Trustees Of Columbia University In The City Of New York Neuronal pain pathway modulators
GB0620259D0 (en) * 2006-10-12 2006-11-22 Astex Therapeutics Ltd Pharmaceutical compounds
US8044041B2 (en) 2006-11-15 2011-10-25 Forest Laboratories Holdings Limited Phthalazine derivatives as inhibitors of protein kinase
AU2008229216B2 (en) 2007-03-20 2013-03-21 Curis, Inc. Fused amino pyridine as HSP90 inhibitors
US7960353B2 (en) * 2007-05-10 2011-06-14 University Of Kansas Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders
JP5766617B2 (ja) * 2009-02-20 2015-08-19 ユニバーシティ・オブ・カンザス 修飾された糖部分を有するノボビオシン類似体
US20110082098A1 (en) 2009-09-30 2011-04-07 University Of Kansas Novobiocin analogues and treatment of polycystic kidney disease
JPWO2012008435A1 (ja) 2010-07-13 2013-09-09 大日本住友製薬株式会社 ビアリールアミド誘導体またはその薬理学的に許容される塩
CN101967125B (zh) * 2010-10-08 2012-07-04 广州暨南生物医药研究开发基地有限公司 一种Hsp90抑制剂Xbj-B16-1及其制备方法与应用
EA024647B1 (ru) 2011-04-05 2016-10-31 Слоун-Кеттеринг Инститьют Фо Кэнсэ Рисерч ИНГИБИТОРЫ Hsp90
WO2012162054A1 (en) 2011-05-20 2012-11-29 The University Of Kansas Dynamic inhibitors of heat shock protein 90
SMT202400145T1 (it) 2012-02-09 2024-05-14 Univ Kansas Intermedi per la preparazione di inibitori c-terminali di hsp90
EP3066072B1 (en) 2013-11-07 2021-11-03 The University of Kansas Biphenylamide derivative hsp90 inhibitors
AU2014346368B2 (en) 2013-11-11 2019-03-14 The University Of Kansas Coumarin based Hsp90 inhibitors with urea and ether substituents
EP3154964B1 (en) 2014-06-13 2023-04-05 The University of Kansas Triazole modified coumarin and biphenyl amide-based hsp90 inhibitors
CA2952029A1 (en) 2014-06-24 2015-12-30 The University Of Kansas Biphenyl amides with modified ether groups as hsp90 inhibitors and hsp70 inducers
EA202092727A1 (ru) 2018-05-14 2021-04-20 Рита Фармасьютикалз, Инк. Биариламиды с модифицированными сахарными группами для лечения заболеваний, связанных с путем белка теплового шока

Also Published As

Publication number Publication date
BR112014019704B1 (pt) 2022-05-31
CN104271587B (zh) 2017-09-12
CA2866814C (en) 2021-02-16
AU2013216858A1 (en) 2014-09-18
EP2812341A1 (en) 2014-12-17
US20240417419A1 (en) 2024-12-19
KR102124109B1 (ko) 2020-06-17
PT2812341T (pt) 2019-11-22
AU2013216858C1 (en) 2018-03-01
CN104271587A (zh) 2015-01-07
US20170051000A1 (en) 2017-02-23
AU2013216858B2 (en) 2017-08-24
EP3656758B1 (en) 2024-03-06
MX2014009608A (es) 2015-05-20
LT2812341T (lt) 2019-12-10
EA201491496A1 (ru) 2015-01-30
DK3656758T3 (da) 2024-04-22
ES2974721T3 (es) 2024-07-01
US10882881B2 (en) 2021-01-05
HRP20240514T1 (hr) 2024-07-05
CN107474085A (zh) 2017-12-15
BR112014019704A2 (it) 2017-06-20
HK1205131A1 (en) 2015-12-11
US20210188891A1 (en) 2021-06-24
PL3656758T3 (pl) 2024-06-10
NZ629778A (en) 2016-03-31
EA027147B1 (ru) 2017-06-30
WO2013119985A1 (en) 2013-08-15
HUE066259T2 (hu) 2024-07-28
SI3656758T1 (sl) 2024-06-28
DK2812341T3 (da) 2019-11-18
RS65412B1 (sr) 2024-05-31
SMT201900660T1 (it) 2020-01-14
CN107474085B (zh) 2021-05-11
US20200283465A1 (en) 2020-09-10
ES2755093T3 (es) 2020-04-21
EP4403552A2 (en) 2024-07-24
HUE046939T2 (hu) 2020-04-28
LT3656758T (lt) 2024-05-10
US10590157B2 (en) 2020-03-17
PL2812341T3 (pl) 2020-03-31
US11390640B2 (en) 2022-07-19
BR112014019704A8 (pt) 2017-07-11
PT3656758T (pt) 2024-03-27
CA2866814A1 (en) 2013-08-15
JP2015506982A (ja) 2015-03-05
US12024536B2 (en) 2024-07-02
US9422320B2 (en) 2016-08-23
FI3656758T3 (fi) 2024-04-22
JP6121450B2 (ja) 2017-04-26
KR20150001729A (ko) 2015-01-06
US20230102047A1 (en) 2023-03-30
HRP20191940T1 (hr) 2020-01-10
SI2812341T1 (sl) 2020-02-28
HK1249519A1 (zh) 2018-11-02
EP3656758A1 (en) 2020-05-27
US20190023730A1 (en) 2019-01-24
US20150057240A1 (en) 2015-02-26
EP2812341B1 (en) 2019-08-28
CY1122358T1 (el) 2021-01-27
US10030041B2 (en) 2018-07-24
RS59719B1 (sr) 2020-01-31
MX361233B (es) 2018-11-30
EP4403552A3 (en) 2024-10-16

Similar Documents

Publication Publication Date Title
HK1243175A1 (zh) 標記的hsp90抑製劑的用途
HK1206023A1 (en) Inhibitors of the fibroblast growth factor receptor
HK1207382A1 (en) Methods for the synthesis of ethylfumarates and their use as intermediates
ZA201305972B (en) Method for the preparation of biphephos
SMT202400145T1 (it) Intermedi per la preparazione di inibitori c-terminali di hsp90
ZA201207397B (en) Process for the preparation of dexlansoprazole
EP2596007A4 (en) PROCESS FOR THE PREPARATION OF 17-DEOXY-CORTICOSTEROIDS
ZA201405824B (en) Process for the preparation of substituted phenylpropanones
ZA201300546B (en) Process for the preparation of 3-haloalkylpyrazoles
PT2390246T (pt) Processo para a preparação de aminaftona
PL391551A1 (pl) Sposób otrzymywania bakteriofagów
ZA201209495B (en) Novel methods for the preparation of p2x7r antagonists
PL2598504T3 (pl) Sposób otrzymywania dimiracetamu
GB201007519D0 (en) Means for inhibiting the expression of rragb
IL224304A (en) A process for making dichlorobulben